Quince Therapeutics (QNCX) announced that the company has completed enrollment in its pivotal Phase 3 NEAT clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics initiated with a Buy at Lucid Capital
- Quince Therapeutics Raises $11.5M in Private Placement
- Quince Therapeutics prices up to $22M placement of securities
- Quince Therapeutics Approves Key Proposals at Annual Meeting
- Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial